Drug General Information (ID: DDIP3M6IV7)
Drug Name			Citalopram		Drug Info		Inotuzumab ozogamicin		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Antidepressants				Antineoplastics

Mechanism of Citalopram-Inotuzumab ozogamicin Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Citalopram				Inotuzumab ozogamicin
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Citalopram and Inotuzumab ozogamicin

Recommended Action
Management		The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.

References
1	Canadian Pharmacists Association.
2	Cerner Multum, Inc. "Australian Product Information.".
3	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
4	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide).".
5	Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
6	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
7	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod).".